Profile data is unavailable for this security.
About the company
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
- Revenue in USD (TTM)19.08m
- Net income in USD-50.53m
- Incorporated2012
- Employees166.00
- LocationProQR Therapeutics NVZernikedreef 9LEIDEN 2333 CKNetherlandsNLD
- Phone+31 854894932
- Websitehttps://www.proqr.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HST Global Inc | 0.00 | -212.63k | 139.70m | 1.00 | -- | 8.48 | -- | -- | -0.0107 | -0.0107 | 0.00 | 0.1167 | 0.00 | -- | -- | -- | -6.87 | -27.80 | -8.09 | -60.19 | -- | -- | -- | -- | -- | -107.48 | 0.0433 | -- | -- | -- | -45.42 | -- | -- | -- |
| Sangamo Therapeutics Inc | 32.88m | -108.91m | 139.77m | 183.00 | -- | 20.18 | -- | 4.25 | -0.4428 | -0.4428 | 0.1326 | 0.0194 | 0.3289 | -- | 5.97 | 179,644.80 | -108.96 | -30.73 | -204.29 | -37.33 | -- | -- | -331.28 | -147.59 | -- | -- | 0.00 | -- | -67.20 | -10.81 | 62.01 | -- | -58.10 | -- |
| Nkarta Inc | 0.00 | -102.61m | 142.06m | 105.00 | -- | 0.4204 | -- | -- | -1.39 | -1.39 | 0.00 | 4.76 | 0.00 | -- | -- | 0.00 | -21.39 | -29.78 | -22.36 | -31.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.41 | -- | 17.99 | -- |
| Tenaya Therapeutics Inc | 0.00 | -94.26m | 145.28m | 97.00 | -- | 1.34 | -- | -- | -0.7875 | -0.7875 | 0.00 | 0.5061 | 0.00 | -- | -- | 0.00 | -76.77 | -47.44 | -87.21 | -51.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.44 | -- | -18.92 | -- |
| Angion Biomedica Corp | 0.00 | -45.86m | 146.91m | 32.00 | -- | 37.99 | -- | -- | -3.15 | -3.15 | 0.00 | 0.2211 | 0.00 | -- | -- | 0.00 | -137.56 | -106.87 | -179.35 | -289.86 | -- | -- | -- | -778.01 | -- | -302.49 | 0.7181 | -- | -- | -- | -47.46 | -- | -18.50 | -- |
| Caribou Biosciences Inc | 9.30m | -157.13m | 148.61m | 147.00 | -- | 1.05 | -- | 15.99 | -1.70 | -1.70 | 0.1004 | 1.52 | 0.0345 | -- | 6.57 | 63,231.29 | -58.27 | -30.69 | -65.59 | -33.30 | -- | -- | -1,690.45 | -562.81 | -- | -- | 0.00 | -- | -71.01 | 11.54 | -46.08 | -- | 40.73 | -- |
| ProQR Therapeutics NV | 19.08m | -50.53m | 149.59m | 166.00 | -- | 2.26 | -- | 7.84 | -0.486 | -0.486 | 0.1837 | 0.6289 | 0.139 | -- | 9.70 | 114,938.80 | -36.82 | -29.87 | -53.74 | -35.27 | -- | -- | -264.83 | -501.81 | -- | -- | 0.2242 | -- | 105.20 | 58.84 | 1.27 | -- | 19.58 | -- |
| Connect Biopharma Holdings Ltd (ADR) | 762.00k | -50.77m | 149.82m | 62.00 | -- | 2.70 | -- | 196.62 | -0.9144 | -0.9144 | 0.0137 | 0.9926 | -- | -- | -- | 12,290.32 | -- | -61.12 | -- | -66.78 | -- | -- | -6,662.99 | -1,963.00 | -- | -- | 0.00 | -- | -- | -- | 74.84 | -- | 37.04 | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -58.01m | 155.01m | 33.00 | -- | 7.56 | -- | -- | -0.8938 | -0.8938 | 0.00 | 0.2407 | 0.00 | -- | -- | 0.00 | -68.07 | -48.63 | -75.01 | -52.10 | -- | -- | -- | -1,201.96 | -- | -73.28 | 0.7327 | -- | -100.00 | -- | 30.44 | -- | -39.67 | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -133.35m | 155.07m | 61.00 | -- | 1.66 | -- | -- | -2.21 | -2.21 | 0.00 | 1.54 | 0.00 | -- | -- | 0.00 | -65.18 | -33.77 | -72.61 | -35.61 | -- | -- | -- | -21,273.47 | -- | -- | 0.2475 | -- | -- | -- | -95.39 | -- | -- | -- |
| Century Therapeutics Inc | 113.34m | -26.48m | 156.46m | 140.00 | -- | 0.8783 | -- | 1.38 | -0.3086 | -0.3086 | 1.32 | 2.04 | 0.3579 | -- | -- | 809,550.00 | -8.36 | -33.69 | -8.95 | -36.94 | -- | -- | -23.36 | -3,876.28 | -- | -- | 0.00 | -- | 194.81 | -- | 7.40 | -- | -42.55 | -- |
| Rani Therapeutics Holdings Inc | 1.20m | -28.32m | 156.76m | 105.00 | -- | -- | -- | 130.64 | -0.7906 | -0.7906 | 0.0322 | -0.1093 | 0.0447 | -- | -- | 11,428.57 | -177.34 | -64.50 | -603.19 | -106.31 | -- | -- | -3,966.50 | -6,123.18 | -- | -14.32 | 8.66 | -- | -- | 0.9816 | 11.63 | -- | -29.88 | -- |
Data as of Feb 11 2026. Currency figures normalised to ProQR Therapeutics NV's reporting currency: US Dollar USD
27.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Adage Capital Management LPas of 30 Sep 2025 | 6.25m | 5.94% |
| Privium Fund Management BVas of 31 Dec 2025 | 5.36m | 5.09% |
| Affinity Asset Advisors LLCas of 30 Sep 2025 | 3.60m | 3.42% |
| abrdn, Inc.as of 31 Dec 2025 | 2.95m | 2.80% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 2.89m | 2.75% |
| Sio Capital Management LLCas of 30 Sep 2025 | 2.08m | 1.97% |
| Kynam Capital Management LPas of 30 Sep 2025 | 1.65m | 1.57% |
| DAFNA Capital Management LLCas of 30 Sep 2025 | 1.57m | 1.49% |
| ArrowMark Colorado Holdings LLCas of 30 Sep 2025 | 1.25m | 1.18% |
| Platinum Investment Management Ltd.as of 30 Sep 2025 | 1.24m | 1.17% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
